{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-gord/goals-outcome-measures/audit-criteria/","result":{"pageContext":{"chapter":{"id":"35e91b3d-56f5-5130-8d0e-f0ad612196a3","slug":"audit-criteria","fullItemName":"Audit criteria","depth":2,"htmlHeader":"<!-- begin field 72e9791c-a7d5-4111-a1fc-8a4b6032251d --><h2>Audit criteria</h2><!-- end field 72e9791c-a7d5-4111-a1fc-8a4b6032251d -->","summary":null,"htmlStringContent":"<!-- begin item 6f1f123e-f370-4551-beac-bfab80caef50 --><!-- begin field 48d2a3d8-cf78-40de-b8f7-14167c0284b5 --><p>The following National Institute of Health and Care Excellence (NICE) audit criteria are relevant for this CKS topic:</p><ul><li>Audit criterion 2. Empirical full-dose proton pump inhibitor (PPI) therapy is offered forÂ 4 or 8 weeks for people with gastro-oesophageal reflux disease (GORD).</li><li>Audit criterion 4. If symptoms of dyspepsia or GORD return after initial care strategies, PPI therapy is stepped down to the lowest dose needed to control symptoms.</li><li>Audit criterion 5. H<sub>2</sub> receptor antagonist (H<sub>2</sub>RA) therapy is offered if there is an inadequate response to a PPI.</li><li>Audit criterion 6. People with GORD who have had dilatation of an oesophageal stricture remain on long-term full-dose PPI.</li><li>Audit criterion 7. People with severe oesophagitis are offered a full-dose PPI for 8 weeks.</li><li>Audit criterion 8. A full-dose PPI is offered long-term as maintenance treatment for people with severe oesophagitis.</li><li>Audit criterion 9. If the person's severe oesophagitis fails to respond to maintenance treatment, a clinical review is carried out.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>]</p><!-- end field 48d2a3d8-cf78-40de-b8f7-14167c0284b5 --><!-- end item 6f1f123e-f370-4551-beac-bfab80caef50 -->","topic":{"id":"83831d3c-e98d-5e82-9fb9-cbd189e834d5","topicId":"8116d56b-de40-4191-af22-5152cc8f533c","topicName":"Dyspepsia - proven GORD","slug":"dyspepsia-proven-gord","lastRevised":"Last revised in April 2017","chapters":[{"id":"2b894900-36e2-56c8-9d00-aea95f9acd57","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"491fd89e-ec21-5541-b37c-3579bd40472f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6d91073e-8bb8-57e8-8ebf-c1b2832b3377","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"69955f21-cf75-5568-9c39-b6894659d140","slug":"changes","fullItemName":"Changes"},{"id":"69e41821-9e9f-506e-bf29-9bb662d19fc5","slug":"update","fullItemName":"Update"}]},{"id":"a5332092-2e76-52c3-9c78-c55c73be1c36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ac987149-bd5e-543a-8025-d0a50c72b165","slug":"goals","fullItemName":"Goals"},{"id":"c282f1cd-c0cd-5cc2-b030-047fa174fc2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"35e91b3d-56f5-5130-8d0e-f0ad612196a3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fac73702-952e-57cf-a136-d52c4400cf78","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8add7bfe-1e06-5768-958d-3c09d529c285","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bb66df20-4142-59d4-913e-cf945ca4dacc","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d0449fde-d38f-58a1-aee2-098d0ab6ff60","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0a206efc-7aca-58e6-8462-5278f905b372","slug":"definition","fullItemName":"Definition"},{"id":"ce8c37c8-0936-52a2-87a7-0cbf130e1ce3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e1423a90-52a5-592c-ba4d-7f5a420ac54a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"cac2f410-0ab9-55d6-8bb8-acbe7735bd9c","slug":"complications","fullItemName":"Complications"},{"id":"9047f011-fcc3-521a-a802-30ac67c85c10","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a4a2f3e7-53b3-50ce-b717-6a6e8e5a219d","fullItemName":"Management","slug":"management","subChapters":[{"id":"6898f6b1-0345-5601-a084-c0f92474d0c9","slug":"dyspepsia-proven-gord","fullItemName":"Scenario: Dyspepsia - proven GORD"}]},{"id":"adea4c6d-b925-5d85-92be-9d322d882faf","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"bda71033-db69-5e58-977e-9d415fe4f646","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"15ddfd64-70ae-5a0e-b1ca-6b8811278010","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"}]},{"id":"dc717df5-19a4-5e7d-8391-be3e281ebdc8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"70508c23-67ec-5f56-b6cd-a9612c7e4e9f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"713a3147-c4ed-5200-a0ab-51e195929400","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a10b2f69-154b-5dcc-8599-ae8de77e7eda","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6155a413-aefc-5575-b07c-111ad7697022","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f73cf98a-26ab-5f78-b8e4-d24d5a849283","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"94379789-e6c4-55fa-b460-965e551f4ea7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"64699d48-46e4-5ff1-97c0-8e280c75065c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a5332092-2e76-52c3-9c78-c55c73be1c36","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}